Please assess the completion status of the following clinical trial:

Trial Title: Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for Major Depressive Disorder Participants:~* Participants must meet DSM-IV-TR criteria for Major Depressive Disorder, with current mood state depressed for ≥ 2 weeks.~* Participants must be females~* Participants must be between the age of 13 and 18 years.~* Participants must have had an adequate trial of fluoxetine, defined as a trial of ≥ 8 weeks of treatment, with a dose of ≥ 40mg daily for ≥ 4 weeks. If the participant had a trial of 40mg daily and was unable to tolerate it, a dose of 20mg for ≥ 8 weeks is acceptable; OR~* Participants must have had an adequate trial of escitalopram, defined as a trial of ≥ 8 weeks of treatment, with a dose of ≥ 20 mg daily for ≥ 4 weeks. If the participant had a trial of 20 mg daily and was unable to tolerate it, a dose of 10 mg for ≥ 8 weeks is acceptable.~* Participants must have a CDRS-R score of ≥ 40 and a CGI-S score of ≥ 4.~* Participants must be able to give informed consent or assent, and where applicable, parent(s)/guardian(s) must be able to give informed permission for study participation.~Inclusion Criteria for Healthy Control Participants:~* Participants must be females~* Participants must be between the age of 13 and 18 years.~* Participants must not meet DSM-IV-TR diagnostic criteria for a psychiatric or substance abuse disorder.~* Participants must be able to give informed consent or assent and, where applicable, parent(s)/guardian(s) must be able to give informed permission for study participation.~Exclusion Criteria for Treatment-Resistant Major Depressive Disorder Participants:~* Unstable co-morbid medical, neurological or psychiatric disorder.~* Pre-existing renal disease.~* Proteinuria or microalbuminuria.~* Pregnant females, nursing mothers, or females of childbearing potential who are unable or unwilling to practice birth control during the study. Participants who are of child-bearing potential must have a negative urine pregnancy test before each MRI/MRS brain scan.~* High risk for suicidal behavior, homicidal behavior or self-harm.~* Adolescents who are unlikely to be able to comply with the study protocol.~* DSM-IV-TR criteria for current substance abuse or substance dependence, with the exception of nicotine abuse or dependence.~* Contraindication to MRI/MRS brain scans, such as ferromagnetic implants or claustrophobic anxiety.~* Documented or suspected history of intellectual disability (Full-Scale I.Q. \< 70).~* History of hypersensitivity to creatine monohydrate.~Exclusion Criteria for Healthy Controls:~* Clinically significant psychiatric or substance abuse disorder.~* Unstable medical or neurological illness.~* Pregnancy, due to the unknown effects of MRI/MRS scanning on a developing fetus.~* Females of childbearing potential who are unable or unwilling to practice contraception during the study.~* Positive urine pregnancy test.~* Contraindication to MRI/MRS scanning, such as ferromagnetic implant or claustrophobic anxiety.~* Documented or suspected history of mental retardation (Full-Scale I.Q. \< 70).

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Open-Label Creatine (Type: EXPERIMENTAL): Creatine Monohydrate 4 grams daily by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete